SCHEMBL7210725

SCHEMBL7210725

O=C(O)C1C2CC(F)(F)CC21

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM2 Q14416 8/20 0.36
GRM3 Q14832 5/20 0.36
GRM8 O00222 3/20 0.36
GRM4 Q14833 3/20 0.36
CYP2C19 P33261 1/20 0.36
POLB P06746 2/20 0.36
TDP1 Q9NUW8 2/20 0.36
GRM6 O15303 4/20 0.35
APLNR P35414 2/20 0.35
GRM5 P41594 4/20 0.33
GRM1 Q13255 2/20 0.33
APEX1 P27695 1/20 0.33
KDM4E B2RXH2 1/20 0.33
GMNN O75496 1/20 0.33
LMNA P02545 1/20 0.33
PMP22 Q01453 1/20 0.33
TFPI2 P48307 1/20 0.33
TP53 P04637 1/20 0.33
TSHR P16473 1/20 0.33
NFKB1 P19838 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15105950 1.00 GRM2 (0.36) GRM2GRM3GRM8GRM4CYP2C19
SCHEMBL15105952 1.00 GRM2 (0.36) GRM2GRM3GRM8GRM4CYP2C19
SCHEMBL16407797 1.00 GRM2 (0.36) GRM2GRM3GRM8GRM4CYP2C19
SCHEMBL15116881 1.00 GRM2 (0.36) GRM2GRM3GRM8GRM4CYP2C19
SCHEMBL15114438 1.00 GRM2 (0.36) GRM2GRM3GRM8GRM4CYP2C19
SCHEMBL31488096 0.77 APLNR (0.33) APLNR
SCHEMBL15116472 0.77 APLNR (0.33) APLNR
SCHEMBL30876236 0.77 APLNR (0.33) APLNR
SCHEMBL15113298 0.73 APLNR (0.31) APLNR
SCHEMBL24174890 0.72 GRM4 (0.50) GRM8GRM4CYP2C19TDP1GRM6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119613408-A Bicyclic ketone compounds and methods of use thereof 豪夫迈·罗氏有限公司 2025-03-14 CN disclosed
CN-110914271-B Bicyclic ketone compounds and methods of use thereof 豪夫迈·罗氏有限公司 2024-12-10 CN disclosed
US-20240300974-A1 BICYCLIC KETONE COMPOUNDS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2024-09-12 US disclosed
EP-4397309-A2 BICYCLIC KETONE COMPOUNDS AND METHODS OF USE THEREOF F. Hoffmann-La Roche AG (CH) 2024-07-10 EP disclosed
EP-3652178-B1 BICYCLIC KETONE COMPOUNDS AND METHODS OF USE THEREOF HOFFMANN LA ROCHE (CH) 2024-01-24 EP disclosed
EP-3652178-B1 BICYCLIC KETONE COMPOUNDS AND METHODS OF USE THEREOF HOFFMANN LA ROCHE (CH) 2024-01-24 EP disclosed
US-11834461-B2 Bicyclic ketone compounds and methods of use thereof GENENTECH, INC. (US) 2023-12-05 US disclosed
US-11834461-B2 Bicyclic ketone compounds and methods of use thereof GENENTECH, INC. (US) 2023-12-05 US disclosed
US-11834461-B2 Bicyclic ketone compounds and methods of use thereof GENENTECH, INC. (US) 2023-12-05 US disclosed
US-11629139-B2 Small molecule inhibitors of Ebola and Lassa fever viruses and methods of use PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2023-04-18 US disclosed
EP-3652178-A1 BICYCLIC KETONE COMPOUNDS AND METHODS OF USE THEREOF H. Hoffnabb-La Roche Ag (CH) 2020-05-20 EP disclosed
US-20190100530-A1 BICYCLIC KETONE COMPOUNDS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2019-04-04 US disclosed
US-20190100530-A1 BICYCLIC KETONE COMPOUNDS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2019-04-04 US disclosed
WO-2019051396-A1 SMALL MOLECULE INHIBITORS OF EBOLA AND LASSA FEVER VIRUSES AND METHODS OF USE PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2019-03-14 WO disclosed
WO-2019012063-A1 BICYCLIC KETONE COMPOUNDS AND METHODS OF USE THEREOF F. HOFFMANN-LA ROCHE AG (CH) 2019-01-17 WO disclosed
WO-2019012063-A1 BICYCLIC KETONE COMPOUNDS AND METHODS OF USE THEREOF F. HOFFMANN-LA ROCHE AG (CH) 2019-01-17 WO disclosed
EP-3019196-B1 COMBINATIONS OF HEPATITIS C VIRUS INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2018-06-06 EP disclosed
EP-1052246-B1 FLUORINE-CONTAINING AMINO ACID DERIVATIVES TAISHO PHARMACEUTICAL CO LTD (JP) 2003-04-02 EP disclosed
US-6316498-B1 FOR THERAPY AND PROPHYLAXIS OF PSYCHIATRIC DISORDERS SUCH AS SCHIZOPHRENIA, ANXIETY, ASSOCIATED DISEASES, DEPRESSION, BIPOLAR DISTURBANCE AND EPILEPSY, NEUROLOGICAL DISEASES SUCH AS DRUG ADDICTION, COGNITION DISORDER, ALZHEIMER'S DISEASE TAISHO PHARMACEUTICAL CO., LTD. (JP) 2001-11-13 US disclosed
EP-1052246-A1 FLUORINE-CONTAINING AMINO ACID DERIVATIVES TAISHO PHARMACEUTICAL CO., LTD (JP) 2000-11-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11629139-B2 Small molecule inhibitors of Ebola and Lassa fever viruses and methods of use CCR8, RPS8, HDHD5 GRM2 4439/4885GRM3 3352/4885GRM8 867/4885
US-20190100530-A1 BICYCLIC KETONE COMPOUNDS AND METHODS OF USE THEREOF HSD17B7, CYP11B1, CYP11B2 GRM2 3228/4885GRM3 2737/4885GRM8 3425/4885
US-11834461-B2 Bicyclic ketone compounds and methods of use thereof HSD17B7, CYP11B1, CYP11B2 GRM2 3228/4885GRM3 2737/4885GRM8 3425/4885
US-20240300974-A1 BICYCLIC KETONE COMPOUNDS AND METHODS OF USE THEREOF HSD17B7, CYP11B1, CYP11B2 GRM2 3228/4885GRM3 2737/4885GRM8 3425/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.